Payments To Physicians
Despite increasing income, many doctors are turning away from self-employment.
Merck buys up Cubist in an $8.4B deal, a jury sides with AstraZeneca in a generic Nexium lawsuit and the NYT finds a correlation between Genentech payments and Lucentis prescriptions.
The pharma payment verification site has been temporarily shut down by CMS due to incorrect information, ProPublica reported today.
Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like meals, travel, gifts, consulting and research
ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.
Facts tucked among the 9.2 million lines of data: 2% of doctors account for around 25% of Medicare billing.
With a new era of transparency for doctors and life science manufacturers kicking off today, here's how some organizations are keeping physicians informed.
With a clear buffet exemption in-hand, the agency's position with respect to CME meals seems pretty clear. Industry is pushing for more clarity around the treatment of accrediting bodies.
The Swiss drug maker is defending itself against two civil fraud lawsuits filed within a week of each other.
AstraZeneca loses in patent court and Pulmicort goes generic, Barbara Ryan joins FTI, Everyday Health and Mayo Clinic expand their advertising alliance, analyst says Ivokana side effect could limit sales
Medtronic rebuffed Senate Finance Committee charges that the company ghostwrote or influenced journal articles about its InFuse bone-growth product while conspiring to paper over adverse events from the treatment.
Allergan removed records from its website that had detailed payments made to doctors from the middle of 2010 through first-half 2011.
The drug industry must move from a mindset that emphasizes compliance with regulations to one steeped in core values of integrity and transparency if it is to regain the public's trust, GSK's Dierdre Connelly said at a conference yesterday.